Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of intact GLP-1 (7-36) and GLP-1 metabolite (9-36) on coronary and peripheral vascular function in adults
2013-001240-64Phase 4Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jul 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of Glucagon-like peptide 1(7-36)-amide, glucagon-like peptide-1 (9-36) and sitagliptin in Coronary Small Vessel Disease (CMD) and cardiac morbidity (3 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Started Jul 2013; status: completed.
02
Drugs
Glucagon-like peptide 1(7-36)-amideglucagon-like peptide-1 (9-36)sitagliptin
03
Conditions
Coronary Small Vessel Disease (CMD)cardiac morbidity
Beyond the preview
Go deeper on 2013-001240-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001240-64.